公司研究 证 券 研 究 报 告 海天瑞声（688787）2025 年报及 2026 年一季报点评 推荐（维持） 具身智能前瞻卡位，数据要素价值释放 当前价：143.95 元 事项： 公司发布 2025 年报及 2026 年一季报，2025 年实现营业收入 3.77 亿元，同比 +59.00%；实现归母净利润 0.14 亿元，同比+24.54%。2026Q1 实现营业收入 9,677.93 万元，同比+38.63%；实现归母净利润 840.30 万元，同比+2,161.14%。 评论： [ReportFinancialIndex] 主要财务指标 | | 2025A | 2026E | 2027E | 2028E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 377 | 549 | 762 | 1,055 | | 同比增速(%) | 59.0% | 45.6% | 38.9% | 38.4% | | 归母净利润(百万) | 14 | 31 | 45 | 70 | | 同比增速(%) | 24.5% | 117.5% | 48.1% | 53.1% | | 每股盈 ...

Key Takeaways OptimizeRx is set to post Q1 results on May 12, with revenues projected to fall 15.9% year over year.OPRX cites weaker managed services demand and conservative pharma spending as key headwinds.The company expects 2026 growth to be backloaded, with stronger performance in the second half.OptimizeRx Corporation (OPRX) will report its first-quarter 2026 results on May 12, after the market close.The Zacks Consensus Estimate for the bottom line in the to-be-reported quarter is pegged at 1 cent, com ...